Tempus AI, Inc. revenue
Tempus AI, Inc.'s revenue was $1.27bn in fiscal 2025, up 83.4% on the year before. Since fiscal 2022 ($321m) it has grown at a compound 58.3% a year. Over the last twelve months it was $1.51bn.
Revenue history
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Diagnostics | $955M | 75.1% | ▲ 111.5% |
| Data and Applications | $316M | 24.9% | ▲ 30.9% |
| Insights Product (part of Data and Applications) | $258M | 81.4% | ▲ 38.0% |
| Trials Product (part of Data and Applications) | $38.5M | 12.2% | ▼ 9.2% |
| AI Applications (part of Data and Applications) | $20.1M | 6.4% | ▲ 63.4% |
From Tempus AI, Inc.'s 10-K filed February 24, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Tempus AI, Inc. | $1.51bn | 36.6% | — |
| Waystar Holding Corp. | $1.26bn | 21.4% | — |
| Omnicell, Inc. | $1.25bn | 8.5% | 0.3% |
| Teladoc Health, Inc. | $2.47bn | -2.4% | -1.5% |
| Goodrx Holdings, Inc. | $785m | -1.8% | 1.8% |
| Veeva Systems Inc | $3.46bn | 16.5% | 15.7% |
Compare with peers
- Waystar Holding Corp. revenue
- Omnicell, Inc. revenue
- Teladoc Health, Inc. revenue
- Goodrx Holdings, Inc. revenue
- Veeva Systems Inc revenue
Head to head: TEM vs WAYOMCL vs TEMTDOC vs TEMTEM vs VEEV
More: Health Care Technology stocks compared, Health Care sector, rankings of US companies